MXPA05010821A - Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. - Google Patents

Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.

Info

Publication number
MXPA05010821A
MXPA05010821A MXPA05010821A MXPA05010821A MXPA05010821A MX PA05010821 A MXPA05010821 A MX PA05010821A MX PA05010821 A MXPA05010821 A MX PA05010821A MX PA05010821 A MXPA05010821 A MX PA05010821A MX PA05010821 A MXPA05010821 A MX PA05010821A
Authority
MX
Mexico
Prior art keywords
opioid antagonist
laxative
peripheral opioid
optionally
formulation
Prior art date
Application number
MXPA05010821A
Other languages
English (en)
Spanish (es)
Inventor
Suketu P Sanghvi
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of MXPA05010821A publication Critical patent/MXPA05010821A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05010821A 2003-04-08 2004-04-08 Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. MXPA05010821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46158503P 2003-04-08 2003-04-08
PCT/US2004/010998 WO2004091665A1 (en) 2003-04-08 2004-04-08 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist

Publications (1)

Publication Number Publication Date
MXPA05010821A true MXPA05010821A (es) 2006-03-30

Family

ID=33299838

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010821A MXPA05010821A (es) 2003-04-08 2004-04-08 Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.

Country Status (10)

Country Link
US (1) US20040259899A1 (https=)
EP (1) EP1638607A1 (https=)
JP (1) JP2006522819A (https=)
CN (1) CN1767855A (https=)
AU (1) AU2004229464A1 (https=)
BR (1) BRPI0409125A (https=)
CA (1) CA2521420A1 (https=)
MX (1) MXPA05010821A (https=)
RU (1) RU2005134364A (https=)
WO (1) WO2004091665A1 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
WO2008052136A2 (en) 2006-10-25 2008-05-02 Proteus Biomedical, Inc. Controlled activation ingestible identifier
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2009022358A1 (en) 2007-08-10 2009-02-19 Luigi Ambrosio Superabsorbent polymer hydro gels and a method of preparing thereof
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5650657B2 (ja) * 2008-12-10 2015-01-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 3−カルボキシプロピル−アミノテトラリン化合物の結晶形態
BR122013009559A2 (pt) 2009-04-28 2019-08-06 Proteus Digital Health, Inc. Marcadores de evento de ingerível altamente confiável e métodos para usar os mesmos
US20100317682A1 (en) * 2009-06-11 2010-12-16 Richard Fuisz Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA123856C2 (uk) * 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
AU2013203559B2 (en) * 2010-03-11 2015-12-03 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
AU2016200133B2 (en) * 2010-03-11 2017-09-07 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2011127252A2 (en) 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
EP2632578A4 (en) * 2010-10-29 2014-12-03 Msd Consumer Care Inc CONCENTRATED THERAPEUTIC SOLUTION
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
CN103338768B (zh) * 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
CN102641496A (zh) 2011-02-16 2012-08-22 辛绍祺 高分子聚合物的新用途及其组成物
PL395069A1 (pl) * 2011-05-31 2012-12-03 Warszawski Uniwersytet Medyczny Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US20180326069A1 (en) * 2011-10-24 2018-11-15 Bayer Healthcare Llc Therapeutic solution concentrate
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
JP2016508529A (ja) 2013-01-29 2016-03-22 プロテウス デジタル ヘルス, インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
WO2014189933A1 (en) * 2013-05-22 2014-11-27 Empire Technology Development Llc Long delayed release laxative
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス, インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
CN109562069B (zh) * 2016-04-25 2022-06-03 吉莱斯公司 治疗便秘的方法
SG10202101937PA (en) 2016-07-22 2021-03-30 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
BR112021022194A2 (pt) * 2019-05-07 2021-12-28 Bausch Health Ireland Ltd Formulações líquidas para dosagem oral de metilnaltrexona
CN115040512B (zh) * 2022-07-28 2023-06-20 苏州中化药品工业有限公司 一种药物组合物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) * 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
EP0143949B1 (en) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
JPS6229515A (ja) * 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
KR940000065B1 (ko) * 1986-08-28 1994-01-05 코 사이 잉 토마스 동물 성장 촉진제
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
WO1993000077A1 (en) * 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
ATE143803T1 (de) * 1992-12-22 1996-10-15 Univ Cincinnati Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
GB2281205A (en) * 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
WO1995030774A1 (en) * 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) * 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
EP0914097B1 (en) * 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
AU6934400A (en) * 1999-08-25 2001-03-19 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
AU2001270134B2 (en) * 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
EP1682006A4 (en) * 2003-10-29 2011-01-26 Physiosonics Inc METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS

Also Published As

Publication number Publication date
RU2005134364A (ru) 2006-06-10
CN1767855A (zh) 2006-05-03
WO2004091665A1 (en) 2004-10-28
US20040259899A1 (en) 2004-12-23
BRPI0409125A (pt) 2006-03-28
JP2006522819A (ja) 2006-10-05
AU2004229464A1 (en) 2004-10-28
EP1638607A1 (en) 2006-03-29
CA2521420A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US20040259899A1 (en) Combination therapy for constipation
RU2373936C2 (ru) Применение метилналтрексона для лечения синдрома раздраженного кишечника
EP2448406B1 (en) Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
AU776099B2 (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
US10624887B2 (en) Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
JP2002533380A (ja) 多孔性粒子を含む剤形
WO2008089260A2 (en) Combined administration of benzonatate and guaifenesin
PT1623703E (pt) Formulações de hidrocodona de libertação controlada
US11744803B2 (en) PH-controlled pulsatile delivery system, methods for preparation and use thereof
JP2013502446A (ja) 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]ピペラジンの新規組成物
CN102143740A (zh) 阿片类拮抗剂治疗尿潴留的用途
WO2007037259A1 (ja) 生体内での崩壊性を向上させたパルス製剤
CN101797253B (zh) 一种岩白菜素、盐酸西替利嗪复方口服剂型
JPH05262767A (ja) 持続性製剤
NZ565272A (en) pH-controlled pulsatile delivery system, methods for preparation and use thereof